Bracco Imaging announces the birth of Blue Earth Therapeutics, a company that will work on precision radiopharmaceuticals initially focused on prostate cancer, but with the aim of extending the range of action to other cancers as well. Blue Earth Therapeutics will take advantage of the successful experience in the development of radiopharmaceuticals of Blue Earth Diagnostics, a fast-growing company acquired by Bracco Imaging in 2019 – recalls the company – to expand its portfolio of nuclear medicine products and apply its expertise to world of next generation therapeutic radiopharmaceuticals.
“We are increasingly committed to precision medicine – says Fulvio Renoldi Bracco, vice president of the board and CEO of Bracco Imaging Spa – Blue Earth Therapeutics will make use of the support of all the skills and resources of Bracco Imaging to strengthen its high-tech platform value to develop innovative therapeutic radiopharmaceuticals for the treatment of cancer patients. The creation of Blue Earth Therapeutics marks an exciting turning point for us in addressing the unmet health needs of patients around the world. “
The new company holds the exclusive worldwide rights for the therapeutic applications of radiopharmaceutical technology targeting prostate specific membrane antigen (Psma). Theranostic radio-hybrid (rh) Psma (rhPsma) drugs – explains a note – have potential utility both in diagnostic imaging and in the treatment of prostate cancer. In fact, they can be labeled with a diagnostic or therapeutic radioisotope. If approved, these innovative experimental compounds offer the possibility of personalized medicine for men with prostate cancer, targeting therapies specifically towards the Psma target of the disease. Specifically, Blue Earth Therapeutics has developed a highly optimized rhPsma therapeutic compound, specifically designed to increase the therapeutic radiation needed to eliminate cancer while minimizing radiation exposure to healthy organs, such as kidney and bone marrow. Administering the lowest possible dose of radiation to healthy tissues is a key principle of nuclear medicine, and is particularly important given that targeted radioligand therapy may be used in the future at an increasingly early stage of prostate cancer progression.
“We are delighted to create Blue Earth Therapeutics in this phase of relaunching nuclear medicine, with the aim of delivering on the promise of targeted radiopharmaceutical therapy in the treatment of patients with life-threatening diseases – says David Gauden, CEO of Blue Earth Therapeutics – Blue Earth Therapeutics has a proven track record in developing radiopharmaceutical therapies, and our early efforts will address the as yet unanswered needs of prostate cancer patients, in which we are continuing our next generation flagship product, the 117Lu beta emission. candidate for clinical trials in the United States and the EU “.
“The initial investment in our company is guaranteed by our founding shareholder, Bracco Imaging – continues the manager – and we have significant synergies shared with our subsidiary Blue Earth Diagnostics: together, these companies provide Blue Earth Therapeutics with a solid platform for success. Short-term opportunities for further investments in the Blue Earth Therapeutics portfolio may include additional prostate cancer indications for our initial product, but also the development of alpha-emitting radiopharmaceuticals and the development and authorization of new compounds in other areas. oncological “.
#Blue #Earth #Therapeutics #born #radiopharmaceuticals #future